RE:RE:GREAT TIME TO INVEST IN FSD FSD Pharma attained the worldwide rights (except for Italy and Spain) of the micronized and ultra-micronized formulations of palmitoylethanolamide (micro-PEA and ultra-micronized-PEA). Prismic had previously acquired the license to conduct R&D and commercialize micronized-PEA and ultra-micronized-PEA as a prescription medication for the relief of inflammation and pain from Epitech Group SpA. Today, Prismic Pharmaceuticals is the core of the FSD Pharma Bioscience Division.